Prologue: Kinins and related systems. New life for old discoveries

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 284, Issue 6 53-6, 2003, Pages

  Skidgel, Randal A ^a   Alhenc Gelas, Francois ^b   Campbell, William B ^c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b INSERM   (France)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; BRADYKININ; BRADYKININ B2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH MOLECULAR WEIGHT KININOGEN; KININ; OMAPATRILAT;

CARDIOVASCULAR SYSTEM; EDITORIAL; HISTORY OF MEDICINE; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 0038782085     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00164.2003     Document Type: Editorial

References (66)

1. Abelous JE and Bardier E. Les substances hypotensives de l'urine humaine normale. CR Soc Biol 66: 511-520, 1909.
2. Bergaya S, Meneton P, Bloch-Faure M, Mathieu E, Alhenc-Gelas F, Levy BI, and Boulanger CM. Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res 88: 593-599, 2001.
3. 2 receptor in human fibroblasts during prolonged agonist exposure. Am J Physiol Heart Circ Physiol 284: H1909-H1916, 2003.
4. 2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270: 13706-13710, 1995.
5. Colman RW, Jameson BA, Lin Y, Johnson D, and Mousa SA. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 95: 543-550, 2000.
6. Colman RW and Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90: 3819-3843, 1997.
7. De Weerd WF and Leeb-Lundberg LM. Bradykinin sequesters B2 bradykinin receptors and the receptor-coupled G-γ subunits Gαq and Gαi in caveolae in DDT1 MF-2 smooth muscle cells. J Biol Chem 272: 17858-17866, 1997.
8. Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, and Erdös EG. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension 31: 912-917, 1998.
9. Elmarakby A, Morsing P, and Pollock DM. Enalapril attenuates endothelin-1 induced hypertension via increased kinin survival. Am J Physiol Heart Circ Physiol 284: H1899-H1903, 2003.
10. Erdös EG. Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K Dahl memorial lecture. Hypertension 16: 363-370, 1990.
11. Erdös EG (Editor). Bradykinin kallidin and kallikrein. In: Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, vol. 25, 1970.
12. Erdös EG (Editor). Bradykinin kallidin and kallikrein. In: Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, 1979, vol. 25, Supplement.
13. Erdös EG (Editor). Kininases. In: Handbook of Experimental Pharmacology. Heidelberg: Springer-Verlag, 1979, p. 427-487.
14. Erdös EG. Kinins, the long march - a personal view. Cardiovasc Res 54: 485-491, 2002.
15. Erdös EG. Perspectives on the early history of angiotensin-converting enzyme (ACE). Recent follow-ups. In: Angiotensin-Converting Enzyme (ACE): Clinical and Experimental Insights, edited by Giles TD. Fort Lee, NJ: Health Care Communications Incorporated, 2001, p. 3-16.
16. Erdös EG, Deddish PA, and Marcic BM. Potentiation of bradykinin actions by ACE inhibitors. Trends Endocrinol Metab 10:223-229, 1999.
17. Erdös EG and Marcic BM. Kinins, receptors, kininases and inhibitors-where did they lead us? Biol Chem 382: 43-47, 2001.
18. Erdös EG and Sloane EM. An enzyme in human blood plasma that inactivates bradykinin and kallidins. Biochem Pharmacol 11:582-592, 1962.
19. Esther CR Jr. Howard TE, Marino EM, Goddard JM, Capecchi MR, and Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 74: 953-965, 1996.
20. 2 bradykinin receptors in transfected cells. Am J Physiol Heart Circ 284: H1892-H1898, 2003.
21. Faussner A, Proud D, Towns M, and Bathon JM. Influence of the cytosolic carboxyl termini of human B1 and B2 kinin receptors on receptor sequestration, ligand internalization, and signal transduction. J Biol Chem 273: 2617-2623, 1998.
22. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, and Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension 30: 535-541, 1997.
23. Gafford JT, Skidgel RA, Erdös EG, and Hersh LB. Human kidney "enkephalinase," a neutral metalloendopeptidase that cleaves active peptides. Biochemistry 22: 3265-3271, 1983.
24. Genden EM and Molineaux CJ. Inhibition of endopeptidase-24.15 decreases blood pressure in normotensive rats. Hypertension 18: 360-365, 1991.
25. Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, Konig W, Knolle J, and Schölkens BA. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102: 769-773, 1991.
26. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, and Erdos EG. Activation of bradykinin B1 receptor by ACE inhibitors. Intern Immunopharmacol 2: 1787-1793, 2002.
27. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, Jennette JC, O'Brien DA, and Smithies O. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375: 146-148, 1995.
28. Linz W, Wiemer G, Gohlke P, Unger T, and Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 47: 25-49, 1995.
29. Marceau F, Hess JF, and Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 50: 357-386, 1998.
30. Marchetti J, Helou CMB, Chollet C, Rajerison R, and Alhenc-Gelas F. ACE- and non-ACE-mediated effect of angiotensin I on intracellular calcium mobilization in the rat glomerular arterioles. Am J Physiol Heart Circ Physiol 284: H1933-H1941, 2003.
31. Marcic B, Deddish PA, Jackman HL, and Erdös EG. Enhancement of bradykinin and resensitization of its B2 receptor. Hypertension 33: 835-843, 1999.
32. Marcic B, Deddish PA, Skidgel RA, Erdös EG, Minshall RD, and Tan F. Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors. J Biol Chem 275: 16110-16118, 2000.
33. Marin-Castano ME, Schanstra JP, Neau E, Praddaude F, Pecher C, Ader JL, Girolami JP, and Bascands JL. Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. Circulation 105: 627-632, 2002.
34. 2+ signaling in single cultured vascular smooth muscle cells. Mol Pharmacol 50: 128-139, 1996.
35. McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, Fujisaki J, Aldrich RW, and Jarnagin K. Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci USA 88: 7724-7728, 1991.
36. Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S, Ceiler D, Gehring D, Martins I, Salmon G, Boulanger CM, Nussberger J, Crozatier B, Gasc JM, Heudes D, Bruneval P, Doetschman T, Menard J, and Alhenc-Gelas F. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci USA 98: 2634-2639, 2001.
37. Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA, Ransom RW, Strader CD, Linemeyer DL, and Hess JF. Expression cloning of a human B1 bradykinin receptor. J Biol Chem 269: 21583-21586, 1994.
38. Millican PE, Kenny AJ, and Turner AJ. Purification and properties of a neurotensin-degrading endopeptidase from pig brain. Biochem J 276: 583-591, 1991.
39. Norman MU, Lew RA, Smith AI, and Hickey MJ. Metalloendopeptidases EC 3.4.24.15/16 regulate bradykinin activity in the cerebral microvasculature. Am J Physiol Heart Circ 284: H1942-H1948, 2003.
40. Norman MU, Reeve SB, Dive V, Smith AI, and Lew RA. Endopeptidases 3 4.24.15 and 24.16 in endothelial cells: potential role in vasoactive peptide metabolism. Am J Physiol Heart Circ Physiol 284: H1978-H1984, 2003.
41. Odya CE, Marinkovic DV, Hammon KJ, Stewart TA, and Erdös EG. Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem 253: 5927-5931, 1978.
42. Ongali B, de Sousa Buck H, Cloutier F, Legault F, Regoli D, Lambert C, Thibault G, and Couture R. Chronic effects of angiotensin-converting enzyme inhibition on kinin receptor binding sites in the rat spinal cord. Am J Physiol Heart Circ 284: H1949-H1958, 2003.
43. Orlowski M, Michaud C, and Chu TG. A soluble metalloendopeptidase from rat brain. Purification of the enzyme and determination of specificity with synthetic and natural peptides. Eur J Biochem 135: 81-88, 1983.
44. Sampaio WO, Nascimento AAS, and Santos RAS. Systemic and regional hemodynamics effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol 284: H1985-H1994, 2003.
45. 1 receptor agonists. Am J Physiol Heart Circ Physiol 284: H1959-H1968, 2003.
46. Schanstra JP, Duchene J, Praddaude F, Bruneval P, Tack I, Chevalier J, Girolami JP, and Bascands JL. Decreased renal NO excretion and reduced glomerular tuft area in mice lacking the bradykinin B2 receptor. Am J Physiol Heart Circ Physiol 284: H1904-H1908, 2003.
47. Schroeder C, Breit A, Böning H, Deido J, Gera L, Stewart J, and Muller-Esterl W. Structural changes in the aminoterminal portion of human B2 receptor selectively increases efficacy of synthetic ligand HOE140 but not of cognate ligand bradykinin. Am J Physiol Heart Circ Physiol 284: H1924-H1934, 2003.
48. Shariat-Madar Z, Mahdi F, and Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277: 17962-17969, 2002.
49. Skidgel RA. Basic carboxypeptidases: regulators of peptide hormone activity. Trends Pharmacol Sci 9: 299-304, 1988.
50. Skidgel RA. Bradykinin-degrading enzymes: structure, function, distribution, and potential roles in cardiovascular pharmacology. J Cardiovasc Pharmacol 20, Suppl 9: S4-S9, 1992.
51. Skidgel RA, Davis RM, and Tan MF. Human carboxypeptidase. Purification and characterization of a membrane-bound carboxypeptidase that cleaves peptide hormones. J Biol Chem 264:2236-2241, 1989.
52. Skidgel RA and Erdös EG. Biochemistry of angiotensin converting enzyme. In: The Renin-Angiotensin System, edited by Robertson JIS and Nicholls MG. London: Gower Medical, 1993, p. 10.11-10.10.
53. Skidgel RA and Erdös EG. Cellular carboxypeptidases. Immunol Rev 161: 129-141, 1998.
54. Skidgel RA and Erdös EG. Enzymatic breakdown of bradykinin. In: Pro-inflammatory and Anti-inflammatory Peptides, edited by Said SI. New York: Dekker, 1998, p. 459-476.
55. Skidgel RA, Johnson AR, and Erdös EG. Hydrolysis of opioid hexapeptides by carboxypeptidase N. Presence of carboxypeptidase in cell membranes. Biochem Pharmacol 33: 3471-3478, 1984.
56. Skidgel RA, Wickstrom E, Kumamoto K, and Erdös EG. Rapid radioassay for prolylcarboxypeptidase (angiotensinase C). Anal Biochem 118: 113-119, 1981.
57. Smith AI, Lew RA, Shrimpton CN, Evans RG, and Abbenante G. A novel stable inhibitor of endopeptidases EC 3.42415 and 342416 potentiates bradykinin-induced hypotension. Hypertension 35: 626-630, 2000.
58. Stewart JM, Gera L, York EJ, Chan DC, and Bunn P. Bradykinin antagonists: present progress and future prospects. Immunopharmacology 43: 155-161, 1999.
59. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, and Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238-33243, 2000.
60. Wang S, Hasham MG, Isordia-Salas I, Tsygankov AY, Colman RW, and Guo YL. Upregulation of Cdc2 and Cyclin A during apoptosis of endothelial cells induced by cleaved high molecular kininogen. Am J Physiol Heart Circ 284: H1917-H1923, 2003.
61. Werle E. Discovery of the most important kallikreins and kallikrein inhibitors. In: Handbook of Experimental Pharmacology, edited by Erdös EG. Heidelberg: Springer-Verlag, 1970, p. 1-6.
62. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henk S, Breipohl G, Konig W, and Knolle J. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 102: 774-777, 1991.
63. Xiao HD, Fuchs S, Cole JM, Disher KM, Sutliff RL, and Bernstein KE. The role of bradykinin in angiotensin converting enzyme (ACE) knockout mice. Am J Physiol Heart Circ Physiol 284: H1969-H1977, 2003.
64. Yang HY, Erdös EG, and Chiang TS. New enzymatic route for the inactivation of angiotensin. Nature 218: 1224-1226, 1968.
65. Yang XP, Saitoh S, Scicli AG, Mascha E, Orlowski M, and Carretero OA. Effects of a metalloendopeptidase-24.15 Inhibitor on renal hemodynamics and function in rats. Hypertension 23: I235-I239, 1994.
66. Zhang JC, Claffey K, Sakthivel R, Darzynkiewicz Z, Shaw DE, Leal J, Wang YC, Lu FM, and McCrae KR. Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5. FASEB J 14: 2589-2600, 2000.